These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 2870354

  • 1. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V.
    Lancet; 1986 Apr 19; 1(8486):880-2. PubMed ID: 2870354
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J.
    Nephrol Dial Transplant; 1989 Apr 19; 4(2):105-9. PubMed ID: 2496350
    [Abstract] [Full Text] [Related]

  • 5. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J.
    Nephron; 1985 Apr 19; 39(4):309-15. PubMed ID: 3982576
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R.
    Nephron; 1992 Apr 19; 60(2):154-63. PubMed ID: 1552999
    [Abstract] [Full Text] [Related]

  • 9. The effects of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment.
    Breuer J, Moniz C, Baldwin D, Parsons V.
    Nephrol Dial Transplant; 1987 Apr 19; 2(5):347-50. PubMed ID: 3122112
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
    Anelli A, Brancaccio D, Damasso R, Padovese P, Gallieni M, Garella S.
    Nephron; 1989 Apr 19; 52(2):125-32. PubMed ID: 2500612
    [Abstract] [Full Text] [Related]

  • 14. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
    Jespersen B, Jensen JD, Nielsen HK, Lauridsen IN, Andersen MJ, Poulsen JH, Gammelgaard B, Pedersen EB.
    Nephrol Dial Transplant; 1991 Apr 19; 6(2):98-104. PubMed ID: 1857534
    [Abstract] [Full Text] [Related]

  • 15. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA, Gouldesbrough D, Smith GD, Cowie JF, Winney RJ.
    Nephrol Dial Transplant; 1989 Apr 19; 4(1):51-6. PubMed ID: 2494599
    [Abstract] [Full Text] [Related]

  • 16. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders.
    Parsons V, Baldwin D, Moniz C, Marsden J, Ball E, Rifkin I.
    Nephron; 1993 Apr 19; 63(4):379-83. PubMed ID: 8459870
    [Abstract] [Full Text] [Related]

  • 17. [Replacement of aluminum-containing phosphate binders by calcium and magnesium carbonates in long-term hemodialysis].
    Zellweger U, Zaugg PY, Dambacher M, Binswanger U, Gautschi K, Hany A.
    Dtsch Med Wochenschr; 1989 Apr 28; 114(17):659-64. PubMed ID: 2707134
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S, Brandi L, Olgaard K.
    Nephrol Dial Transplant; 1996 Aug 28; 11(8):1586-91. PubMed ID: 8856216
    [Abstract] [Full Text] [Related]

  • 20. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation.
    Morinière P, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, Hocine C, Marie A, Leflon P, Roche D.
    Nephrol Dial Transplant; 1988 Aug 28; 3(5):651-6. PubMed ID: 3146723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.